The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
International, expanded access program of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy (VEGFr-TKI): Subanalysis from emerging growth market (EGM) countries.
Se-Hoon Lee
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Expert Testimony - Bayer; Novartis; Pfizer
Suleyman Buyukberber
No relevant relationships to disclose
Yen-Chuan Ou
No relevant relationships to disclose
Jeremy David Shapiro
Consultant or Advisory Role - Merck
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Ozlem Ocak Arikan
Employment or Leadership Position - Novartis
Hong-Ling Xue
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Igor Rusakov
No relevant relationships to disclose